UFP Technologies
UFPT
$334.84
+25.16%
UFP Technologies Inc is a contract development and manufacturing organization (CDMO) specializing in single-use and single-patient medical devices, serving top-tier medical device manufacturers globally. The company occupies a critical niche in the medical device supply chain as a valued outsource partner, converting raw materials through advanced manufacturing techniques like laminating, molding, and RF welding. Currently, the investor narrative centers on the company's consistent revenue growth trajectory, expanding margins, and its ability to capitalize on the broader trend of medical device outsourcing, though recent stock price volatility has sparked debate about valuation sustainability.…
UFPT
UFP Technologies
$334.84
Investment Opinion: Should I buy UFPT Today?
Rating: Hold. UFPT is a well-run medical device CDMO with consistent growth and solid margins, but the stock's recent underperformance and premium valuation warrant a cautious stance. The analyst consensus is Buy with an average target of $324.50, implying 32% upside, but limited coverage and high volatility temper enthusiasm.
Supporting Evidence: Revenue grew 4.09% YoY to $154.2M in Q1 2026, with operating margin improving to 15.1%. The trailing P/E of 25.0x is reasonable relative to its historical range (8.3x-40.8x) and the PEG ratio of 1.63 suggests fair value. Free cash flow TTM of $69.4M and ROE of 16.1% underscore profitability. However, the 1-year price return of +6.37% lags the S&P 500, and the stock's beta of 1.07 offers no downside protection.
Risks & Conditions: The Hold rating could upgrade to Buy if the stock pulls back to a P/E below 20x (around $196) or if revenue growth accelerates above 10%. A downgrade to Sell would be warranted if gross margins fall below 25% or if the company loses a major customer. Overall, UFPT appears fairly valued relative to its history and growth, but not a clear bargain at current levels.
Sign up to view all
UFPT 12-Month Price Forecast
UFPT is a fundamentally sound company with a solid growth trajectory and healthy margins. However, the stock's recent underperformance and premium valuation relative to the market create a neutral outlook. The base case of 4-5% growth and stable margins is most probable, leading to modest upside. A bullish stance would require evidence of accelerating growth or a pullback to a more attractive valuation. A bearish stance would be triggered by margin erosion or customer concentration issues. Given the limited analyst coverage and high volatility, a neutral stance with medium confidence is appropriate.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on UFP Technologies's 12-month outlook, with a consensus price target around $324.50 and implied upside of -3.1% versus the current price.
Average Target
$324.50
0 analysts
Implied Upside
-3.1%
vs. current price
Analyst Count
—
covering this stock
Price Range
$289 - $360
Analyst target range
Only 2 analysts cover the stock, with a consensus recommendation leaning bullish (all Buy ratings from Lake Street and Colliers Securities). The average target price is $324.50, implying 32.0% upside from the current price of $245.93. The target range spans from $289.00 (low) to $360.00 (high), representing 17.5% to 46.4% upside. The wide spread of $71 between low and high targets indicates high uncertainty about the company's future performance. The high target likely assumes accelerating revenue growth and margin expansion, while the low target may price in competitive pressures or slower industry growth. The limited analyst coverage (2 analysts) is typical for a mid-cap stock with a market cap of $1.71 billion, which can lead to less efficient price discovery and higher volatility. Recent ratings from Lake Street have been consistently bullish, with no downgrades in the past year.
Bulls vs Bears: UFPT Investment Factors
UFPT presents a balanced risk/reward profile. On the bull side, the company demonstrates consistent revenue growth, expanding margins, a strong balance sheet, and significant upside to analyst targets. On the bear side, limited analyst coverage, recent underperformance, and a premium valuation relative to the market introduce uncertainty. The most important tension is whether the company can sustain its growth trajectory and margin expansion to justify its current P/E of 25x. If growth accelerates, the stock could re-rate higher; if it decelerates, multiple compression could erase gains. Currently, the bull case has slightly stronger evidence given the solid fundamentals and analyst confidence, but the stock's volatility warrants caution.
Bullish
- Strong Revenue Growth Trajectory: Revenue grew 4.09% YoY in Q1 2026 to $154.2M, accelerating from $144.1M in Q4 2024. The multi-quarter trend shows consistent expansion, driven by the Product segment ($151.8M), indicating robust demand for single-use medical devices.
- Healthy Profitability and Margins: Net income of $17.5M in Q1 2026 with a net margin of 11.3% and operating margin of 15.1%, up from 14.4% in Q4 2025. Gross margin is stable at 28.8%, reflecting pricing power and operational efficiency.
- Solid Balance Sheet and Cash Flow: Debt-to-equity is low at 0.36, current ratio is 2.68, and trailing twelve-month free cash flow is $69.4M. This financial strength provides flexibility for organic growth or acquisitions.
- Attractive Analyst Upside Potential: The average analyst target is $324.50, implying 32.0% upside from the current price of $245.93. The high target of $360 suggests 46.4% upside, reflecting confidence in the company's growth story.
Bearish
- Limited Analyst Coverage and Uncertainty: Only 2 analysts cover UFPT, with a wide target spread of $71 (low $289 to high $360). This limited coverage can lead to inefficient price discovery and higher volatility, as seen in the stock's 30.69% max drawdown over the past year.
- Recent Underperformance vs. Market: The 1-year price change of +6.37% significantly underperforms the S&P 500's +20.92%. The 6-month change of -5.60% also lags the market, indicating persistent relative weakness despite a recent rebound.
- Valuation Premium to Broader Market: Trailing P/E of 25.0x is above the S&P 500 average of ~20x. While justified by growth, any slowdown in revenue or margin expansion could lead to multiple compression, especially in a rising rate environment.
- Concentration Risk in Medical Devices: UFPT's revenue is heavily concentrated in the medical device sector, making it vulnerable to regulatory changes, reimbursement shifts, or supply chain disruptions. The company's niche focus limits diversification.
UFPT Technical Analysis
The stock is in a recovery phase after a significant correction, with the current price of $245.93 sitting 88% of the way from the 52-week low of $173.86 to the high of $279.49. The 1-year price change of +6.37% underperforms the S&P 500's +20.92%, indicating relative weakness over the long term, but the stock has rebounded sharply from its March 2026 lows near $186. Short-term momentum is strongly positive: the 1-month change is +5.25% and the 3-month change is +26.74%, both outpacing the S&P 500's respective gains of 0.6% and 6.29%. This divergence from the tepid 1-year return suggests a potential trend reversal or mean reversion, as the stock has recaptured its 50-day moving average and is approaching the 200-day. The 52-week high of $279.49 represents a key resistance level; a breakout above that would signal a resumption of the prior uptrend, while a breakdown below the 52-week low of $173.86 would indicate further downside. The stock's beta of 1.07 implies roughly in-line volatility with the market, but the 6-month price change of -5.60% versus the S&P 500's +9.13% highlights recent underperformance that is now being reversed.
Beta
1.06
1.06x market volatility
Max Drawdown
-30.7%
Largest decline past year
52-Week Range
$174-$339
Price range past year
Annual Return
+48.0%
Cumulative gain past year
| Period | UFPT Return | S&P 500 |
|---|---|---|
| 1m | +22.9% | +3.6% |
| 3m | +53.5% | +5.1% |
| 6m | +30.7% | +13.8% |
| 1y | +48.0% | +22.2% |
| ytd | +49.9% | +13.1% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
UFPT Fundamental Analysis
Revenue has grown steadily, with Q1 2026 revenue of $154.2 million representing a 4.09% year-over-year increase from Q1 2025's $148.1 million. The multi-quarter trend shows revenue accelerating from $144.1 million in Q4 2024 to $154.2 million in Q1 2026, driven by the Product segment ($151.8 million) which accounts for the vast majority of sales. The company is profitable, with Q1 2026 net income of $17.5 million and a gross margin of 28.8%, which has been relatively stable over the past year (ranging from 28.2% to 28.8%). Operating margin improved to 15.1% in Q1 2026 from 14.4% in Q4 2025, indicating modest operating leverage. The balance sheet is healthy: debt-to-equity is a low 0.36, and the current ratio stands at 2.68, providing ample liquidity. Free cash flow for the trailing twelve months is $69.4 million, though Q1 2026 operating cash flow was only $3.2 million due to working capital build; the company has generated positive free cash flow in each of the last four quarters, averaging $18.2 million per quarter. ROE is a solid 16.1%, reflecting efficient use of equity capital.
Quarterly Revenue
$154202000.0B
2026-03
Revenue YoY Growth
+4.1%
YoY Comparison
Gross Margin
28.8%
Latest Quarter
Free Cash Flow
$69444000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is UFPT Overvalued?
Since net income is positive, the trailing P/E ratio of 25.0x is the primary valuation metric. The forward P/E of 21.0x implies earnings growth is expected, and the PEG ratio of 1.63 suggests the stock is reasonably priced relative to its growth rate. Compared to the industry average (not provided), the stock's P/E of 25.0x appears elevated relative to the broader market, but the company's strong margins and growth profile may justify a premium. Historically, the trailing P/E has ranged from 8.3x (Q3 2022) to 40.8x (Q4 2021), and the current 25.0x is near the midpoint of that range, suggesting valuation is neither stretched nor distressed. The price-to-book ratio of 4.04x is below its 5-year average of roughly 5.0x, indicating potential value relative to book value. The EV/EBITDA of 15.9x is reasonable for a profitable medical device CDMO.
PE
25.0x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 17x~41x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
15.9x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: UFPT's financial health is solid, but the low debt-to-equity of 0.36 and current ratio of 2.68 provide a cushion. However, Q1 2026 operating cash flow of only $3.2M, compared to the trailing average of $18.2M per quarter, signals potential working capital strain. The company's net margin of 11.3% is respectable but could be pressured if raw material costs rise or pricing power weakens. Revenue concentration in the medical device sector (100% of sales) amplifies operational risk from any industry-specific downturn.
Market & Competitive Risks: The stock's beta of 1.07 indicates roughly market-level volatility, but its 1-year relative strength of -14.55% versus the S&P 500 shows persistent underperformance. The trailing P/E of 25.0x is above the market average, making it vulnerable to valuation compression if growth disappoints. Limited analyst coverage (only 2 analysts) reduces price discovery and can lead to sharp moves on news. Competitive threats from larger CDMOs or in-house manufacturing by clients could erode market share.
Worst-Case Scenario: In a severe downturn, a combination of revenue deceleration, margin compression, and multiple contraction could drive the stock to its 52-week low of $173.86, representing a 29.3% decline from the current price of $245.93. This scenario could be triggered by a major customer loss, regulatory headwind, or broader market sell-off. The historical max drawdown of -30.69% suggests such a decline is within the realm of possibility.
FAQ
The key risks are: 1) Financial: Low operating cash flow in Q1 2026 ($3.2M) could signal working capital issues, though TTM FCF is strong at $69.4M. 2) Competitive: As a niche CDMO, UFPT faces competition from larger players and the risk of customers moving production in-house. 3) Macro: With a beta of 1.07, the stock is sensitive to market downturns, and its premium P/E of 25x could compress in a rising rate environment. 4) Company-specific: Revenue concentration in medical devices makes it vulnerable to regulatory changes or reimbursement cuts. The most severe risk is a 29% decline to the 52-week low of $173.86.
The 12-month forecast is mixed. The bull case (30% probability) sees the stock reaching $289-$360, driven by accelerating growth and margin expansion. The base case (45% probability) targets $245-$290, assuming steady 4% growth and stable margins. The bear case (25% probability) sees a decline to $174-$220 if growth decelerates or margins compress. The most likely scenario is the base case, with the stock trading near current levels or modestly higher. Key assumptions include sustained revenue growth of 4-5% and gross margins above 28%.
UFPT's trailing P/E of 25.0x is near the midpoint of its 5-year range (8.3x-40.8x) and below its 5-year average of roughly 30x, suggesting it is fairly valued relative to its own history. Compared to the broader market (S&P 500 P/E ~20x), it trades at a premium, which is typical for a growth company. The price-to-book ratio of 4.04x is below the 5-year average of 5.0x, indicating potential value on a book basis. The PEG ratio of 1.63 suggests the stock is reasonably priced relative to its expected earnings growth. Overall, UFPT appears fairly valued, with the market pricing in steady but not explosive growth.
UFPT is a good buy for investors with a long-term horizon who are comfortable with moderate volatility. The company has consistent revenue growth (4.09% YoY), solid margins (28.8% gross, 15.1% operating), and a strong balance sheet (debt-to-equity 0.36). Analyst targets imply 32% upside to $324.50, but limited coverage (2 analysts) and a wide target range ($289-$360) add uncertainty. The biggest downside risk is a 29% decline to the 52-week low of $173.86 if growth stalls. For growth-oriented investors, it's a buy on pullbacks; for value investors, it's a hold until a better entry point.
UFPT is better suited for long-term investment due to its steady growth profile and solid fundamentals. The stock's beta of 1.07 indicates moderate volatility, but its 1-year relative strength of -14.55% versus the S&P 500 suggests it may underperform in the short term. The company pays no dividend, so returns come from capital appreciation. With a PEG ratio of 1.63 and consistent revenue growth, a minimum holding period of 3-5 years is recommended to allow the growth story to play out. Short-term traders may find opportunities around earnings, but the limited analyst coverage and wide target range increase uncertainty.